SAMSUNG-BIOEPIS
Samsung Bioepis Co., Ltd. today announced its expansion into the Brazilian biopharmaceutical market. The first product available in the country is BRENZYS™ (etanercept), a biosimilar referencing ENBREL® .i BRENZYS™ was approved by Agência Nacional de Vigilância Sanitária (ANVISA), the country’s health regulatory agency, in December 2017 for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and non-radiographic axial spondyloarthritis.
Samsung Bioepis is continuing its business expansion in multiple markets across the world, including mainland China, where the company entered into partnerships with 3SBio and C-Bridge Capital to develop and commercialize multiple biosimilar candidates from Samsung Bioepis.
BRENZYS™ is being supplied to Sistema Único de Saúde (SUS), the country’s public health system, through a Productive Development Partnership (PDP) between Samsung Bioepis and local partners, Bionovis and Bio-Manguinhos/Fiocruz.
Under the PDP, Samsung Bioepis will supply biosimilar products or product intermediaries to the local partners for sale to SUS for a period of 10 years. During this period, Samsung Bioepis will provide technology transfer to the local partners, so that manufacturing responsibilities can be gradually transferred to enable local manufacturing in Brazil. The PDP scheme was introduced by the Brazilian government in 2008, in order to expand access to medicines and support the country’s pharmaceutical industry through technology transfer from established companies in return for guaranteed purchases from SUS.
In Brazil, over 75% of patients nationwide rely on SUS for health care coverage.ii While biologics represent approximately 4% of all medicinal products acquired by SUS, they account for approximately 51% of government spending on medicinal products.iii
“We are excited to provide our high-quality biosimilars to patients across Brazil, and look forward to working with our local partners to enhance patient access to high-quality healthcare. Equally important, by sharing our scientific knowledge with our local partners, we hope to do our part in contributing to the long-term development of the Brazilian biopharmaceutical industry,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and health care systems across the world.”
Samsung Bioepis’ products are now available across five continents: North America, Europe, Asia, Oceania, and Latin America. The company currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab), as well as an oncologic biosimilar, ONTRUZANT® (trastuzumab). Over 170,000 patients are currently under treatment with Samsung Bioepis’ biosimilars in Europe. In the United States, the company has one biosimilar – RENFLEXIS® (infliximab-abda) – approved and marketed. ONTRUZANT® (trastuzumab-dttb) received approval from the U.S. Food and Drug Administration (FDA) in January 2019, while ETICOVO™ (etanercept-ykro) and HADLIMA™ (adalimumab-bwwd) received FDA approval in April and July 2019, respectively.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
_____________________________
i
ENBREL is a registered trademark of Pfizer
ii
Jurberg C, Humphreys G. Brazil's march towards universal coverage. Bull World Health Organ
. 2010;88(9):646-7.
iii
Debiasi M, et al. Biosimilars in Brazil: The Beginning of an Era of Broader Access. Journal of Cancer Therapy
. 2017; 8:814-826.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Torq Crushes EMEA Estimates With Record-Breaking Q3, Hitting 185% of Quarterly Target19.11.2025 15:00:00 CET | Press release
Torq Achieves 284%EMEA Customer Growth As It Signs Iconic Enterprises Including Virgin Atlantic, Kyocera, Siemens, and Zara Torq, the autonomous security operations leader, today announced it has exceeded Q3 EMEA revenue estimates, achieving 185% of its quarterly target. Torq is now firmly established as EMEA’s autonomous security operations platform of choice as enterprise goliaths continue joining its customer ranks, including Virgin Atlantic, Kyocera, Siemens, and Zara. Torq’s EMEA headcount grew 400% across 2025 to accommodate the exponentially increasing demand. “As worldwide momentum accelerates, Torq is doubling down on its EMEA investment by expanding operations, growing regional leadership, and strengthening our on-the-ground presence to fuel our next stage of growth,” said Ofer Smadari, CEO and co-founder, Torq. “Torq is now trusted by many of the world’s largest brands inside some of the most complex and sophisticated security operations centers. With new expansion into Germ
iConnections Launches Pipelines: A Powerful New Way for LPs and GPs to Turn Connections Into Real Momentum19.11.2025 15:00:00 CET | Press release
iConnections, the leading network for allocators and fund managers, today announced the launch of Pipelines, a new productivity and relationship-management tool built directly into the platform. Pipelines gives LPs and GPs a structured, visual, and purpose-built way to organize their outreach, nurture relationships, and drive their fundraising or investment processes forward—without relying on fragmented spreadsheets or generic CRMs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119021208/en/ Born from extensive feedback across the alternative investment ecosystem, Pipelines is designed to solve a common industry challenge: after a productive event or outreach cycle, promising conversations often lose momentum because there is no simple, tailored way to track next steps. “With Pipelines, users finally have a workflow that matches the way this industry actually operates,” said Douglas Melchior, VP of Product at iConnectio
Xsolla Releases “The Xsolla Report: State of Play Q3 2025 Edition, Vol. 8,” Delivering Clear, Data-Led Insights for Game Developers19.11.2025 15:00:00 CET | Press release
Report Unpacks Regional Trends Across China, Europe, and MENA to Inform Growth, Monetization, and Player Engagement Strategies Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their products, today announces the release of The Xsolla Report: State of Play Q3 2025 Edition, Vol. 8, a comprehensive analysis of market forces shaping the games industry. The report synthesizes the latest data and expert perspectives to help developers and publishers plan for sustainable growth across platforms and regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119397781/en/ Graphic: Xsolla As developers navigate new distribution models and evolving monetization approaches, the Q3 2025 edition offers a practical perspective on where the market is heading. The global player base is projected to reach 3.6 billion by year-end, with revenue on track to reach $188.8 billion—driven by steady moment
PicSee Launches the World’s First Social Platform That Helps You Get All Your Photos from Friends19.11.2025 15:00:00 CET | Press release
Built on Mutual Photo Sharing and Powered by AI PicSee, a new kind of social platform, announced its global launch - introducing a revolutionary way for friends and family to reconnect through photos. Built on mutual photo sharing and powered by AI, PicSee helps users automatically get all their photos from friends by giving them theirs - without ever uploading them to the cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112904808/en/ PicSee App - Home Screen Every year, trillions of photos are captured but rarely shared with the friends in them. PicSee changes that. Using on-device facial recognition and a patent-pending “give to get” system, the app automatically identifies which photos belong to whom and helps friends exchange them securely with a single tap. PicSee scans a user’s gallery, recognizes faces, and generates a personalized invite such as: “I have 75 of your pics. Come get them on PicSee.” Once two fri
Frontgrade’s Next-Generation SADA-10 Enhances Satellite Power System Efficiency for LEO and MEO Missions19.11.2025 13:30:00 CET | Press release
Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions,today announced the SADA-10, a compact Solar Array Drive Assembly (SADA) engineered to deliver precise, reliable solar array positioning for Low and Medium Earth Orbit missions. Designed with the latest technology for New Space and leveraging Frontgrade learnings from heritage systems, the SADA-10 combines flight-proven reliability with optimized size, weight, power, and cost (SWaP-C) to give customers greater efficiency and mission assurance in a smaller footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119865921/en/ The SADA-10’s hybrid stepper motor and harmonic gear drive provide high torque output, zero backlash, and accuracy of 0.015°, ensuring precise solar tracking and maximum power generation in orbit. Dual potentiometers enable redundant position sensing for reliable performance,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom